Drug Trial Radar · NCT07213960
A Sequential Phase 2/3 Study of APL2 in Patients With Focal Segmental Glomerulosclerosis
Last checked: Nov 20, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
270
Planned (sponsor's estimate)
Start
Dec 2026
Primary completion
Oct 2029
Study completion Dec 2029
Sponsor
- Lead sponsor
- Apellis Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 9, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a sequential phase 2/3 study to evaluate the efficacy and safety of twice-weekly subcutaneous (SC) infusions of APL2 in patients diagnosed with FSGS. The initial phase 2 portion is a single-arm, open-label study in adults diagnosed with FSGS. Phase 2 will commence prior to randomizing for phase 3. The phase 3 portion of the study is a randomized, placebo-controlled, double-blinded, multicenter study in adults and adolescents diagnosed with FSGS.
Conditions
- FSGS
Interventions
APL2Drug
Complement (C3) Inhibitor
PlaceboOther
Sterile solution of equal volume to active arm
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 2: Evaluate the efficacy of APL2 in terms of change from baseline in log-transformed urine protein to creatinine ratio (uPCR)Time frame: Baseline to Week 12
- Phase 3: Change from baseline in log-transformed urine protein to creatinine ratio (uPCR)Time frame: Baseline to Week 52
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Investigator Site 1
Chicago, Illinois · Recruiting
Investigator Site 2
New York, New York · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.